Overview

Pembrolizumab for Smoldering Multiple Myeloma (SMM)

Status:
Recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if Keytruda (pembrolizumab) can help to control intermediate- or high-risk smoldering multiple myeloma (SMM). The safety of this drug will also be studied.

Phase:

N/A

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab